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retinal vessel function, and the common carotid intima-me-
dia thickness (IMT). The main secondary endpoint was the 
change in different biochemical markers.  Results: After 9 
months, no relevant differences could be determined in the 
two treatment groups in PWV (pioglitazone 14.3 ± 4.4 m/s vs. 
placebo 14.2 ± 4.2 m/s), retinal arterial diameter (piogli-
tazone 112.1 ± 23.3 μm vs. placebo 117.9 ± 21.5 μm) or IMT 
(pioglitazone 0.85 ± 0.30 mm vs. placebo 0.79 ± 0.15 mm). 
Additionally, there were no differences in the change in bio-
chemical markers like cholesteryl ester transfer protein, low-
density lipoprotein cholesterol, high-sensitivity C-reactive 
protein or white blood cell count.  Conclusions : Treatment 
with a peroxisome proliferator-activated receptor-γ agonist 
in nondiabetic patients did not improve the function of large 
and small peripheral vessels (PPP Trial, clinicaltrialsregister.
eu: 2006-000186-11).  © 2015 S. Karger AG, Basel 
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 Abstract 
 Objective: Despite the advanced therapy with statins, anti-
thrombotics, and antihypertensive agents, the medical 
treatment of atherosclerotic disease is less than optimal. 
Therefore, additional therapeutic antiatherosclerotic op-
tions are desirable. This pilot study was performed to assess 
the potential antiatherogenic effect of the peroxisome pro-
liferator-activated receptor-γ agonist pioglitazone in nondi-
abetic patients.  Methods: A total of 54 nondiabetic patients 
were observed in a prospective, double-blind, placebo-con-
trolled study. Patients were randomized to pioglitazone or 
placebo. The following efficacy parameters were deter-
mined by serial analyses: artery pulse wave analysis and ca-
rotid-femoral pulse wave velocity (PWV), static and dynamic 
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 Atherosclerosis is a chronic systemic disease that is 
mainly caused by a chronic inflammation of the arterial 
walls  [1] . This widespread disease affects the large arteries 
like the aorta as well as the small vessels like the retinal 
vessels and causes pathological vessel wall stiffness. Thus, 
increased aortic stiffness is a strong independent predic-
tor of all-cause and mainly cardiovascular mortality  [2] . 
Thereby, the chronic local vessel wall inflammation is 
triggered by numerous inflammatory cells like macro-
phages and T lymphocytes  [3, 4] . Because of this proin-
flammatory milieu in atherosclerotic plaques, a systemic 
anti-inflammatory drug therapy for plaque stabilization 
is promising. For example, it could be demonstrated that 
statin administration led to stabilization of atherosclerot-
ic lesions  [5, 6] . However, Bayturan et al.  [7] were able to 
show that, despite achieving very low levels of low-densi-
ty lipoprotein (LDL) cholesterol, more than 20% of pa-
tients had atherosclerotic plaque progression. These data 
suggested that statin therapy is only one component of 
successful secondary prevention in patients suffering 
from atherosclerosis. Therefore, novel antiatherosclerot-
ic drug therapies would be desirable.
 Another potential antiatherogenic agent is the thiazoli-
dinedione pioglitazone. Pioglitazone is an agonist of per-
oxisome proliferator-activated receptor-γ used for the 
treatment of type 2 diabetes  [8, 9] . It reduces the levels of 
different inflammatory markers, such as high-sensitivity 
C-reactive protein (hsCRP), independently of its effect on 
glycemic metabolism  [10] . The PROactive study could 
show a reduction of a composite of all-cause mortality, 
nonfatal myocardial infarction and stroke in patients with 
type 2 diabetes under treatment with pioglitazone  [11] . In 
the PERISCOPE trial, treatment with pioglitazone result-
ed in a significantly lower rate of progression of coronary 
atherosclerosis compared with glimepiride in patients 
with type 2 diabetes  [12] . A previous study demonstrat-
ed a stabilization of coronary artery plaques and a delay 
of plaque size progression in nondiabetic patients  [13] . 
Whether these positive effects on systemic plaque stabili-
zation also exist in nondiabetic patients is unknown. 
 The Pioglitazone on Plaque Progression Trial (PPP Tri-
al) evaluated the effect of pioglitazone on vessel wall func-
tion of large and small arteries as well as clinical and labora-
tory data as surrogate parameters for atherosclerotic plaque 
progression in nondiabetic patients. Therefore, carotid inti-
ma-media thickness (IMT), static and dynamic retinal ves-
sel analysis, and pulse wave velocity (PWV) were measured 
before and after administration of pioglitazone for 9 months.
 Methods 
 Study Design 
 The Dresden PPP Trial was a double-blind, placebo-controlled, 
double-center study performed in compliance with the guidelines 
for good clinical practice and the Declaration of Helsinki. The 
study was approved by the institutional ethics committee at each 
participating site and written informed consent was obtained from 
each patient prior to enrollment in the study. All data were col-
lected, managed and analyzed at the Department of Cardiology of 
the University Magdeburg and at the Heart Centre, University of 
Dresden (clinicaltrialsregister.eu Identifier: 2006-000186-11).
 The main observed clinical efficacy parameters of this pilot 
study were the change in (1) artery pulse wave analysis and carot-
id-femoral PWV, (2) static and dynamic retinal vessel analysis, (3) 
measure of the common carotid IMT and (4) body weight and 
blood pressure.  The secondary efficacy endpoint was the influence 
of pioglitazone on different biochemical markers like cholesteryl 
ester transfer protein (CETP) concentration and activity, white 
blood cell count, and hsCRP.
 Study Population and Protocol 
 Eligible subjects were male or female nondiabetic patients 18–
80 years of age with unstable angina pectoris or non-ST-elevation 
myocardial infarction caused by coronary heart disease requiring a 
stent. The main exclusion criteria were the presence of overt diabe-
tes mellitus, ST-elevation myocardial infarction and a known intol-
erance to pioglitazone or previous treatment with thiazolidine-
diones. The detailed inclusion and exclusion criteria are listed in 
 table 1 of the supplements. When a patient fulfilled all clinical in-
clusion criteria and none of the clinical exclusion criteria, written 
consent of the patient was obtained and a coronary angiography 
was performed within 48 h according to the guidelines. After the 
angiography, all of the above-mentioned baseline blood samples 
were drawn and baseline clinical data were measured. The obtained 
baseline data were stored and analyzed in a core laboratory (Heart 
Center Dresden). After completion of all baseline investigations, 
the enrolled study subjects were randomly assigned either to the 
pioglitazone group (n = 27) or to the placebo group (n = 27). The 
pioglitazone group received 30 mg/day of pioglitazone in addition 
to the standard medical treatment. The additional medication after 
the index event could be adjusted by the responsible physician, with 
the exception of the lipid-lowering therapy, which was given in a 
fixed dose of 20 mg of atorvastatin in both treatment groups. Suc-
cessfully enrolled and randomized patients entered the observation 
phase of the study and medical treatment with pioglitazone or pla-
cebo was continued for up to 9 months. Two follow-up visits at the 
outpatient clinic were scheduled 2 and 6 months after randomiza-
tion to confirm patient compliance as well as to verify secondary 
safety endpoints and the compatibility of the study medication. 
Safety assessments included 12-lead ECG, clinical laboratory pa-
rameters, and physical examination. At the final follow-up visit 9 
months after randomization, all biochemical markers and clinical 
data were obtained for a second time. Finally, at the 9-month fol-
low-up visit, potential adverse events were recorded. A detailed list 
of all study visits and examinations is available in  table 2 .
 Artery Pulse Wave Analysis and Carotid-Femoral PWV 
 For the pulse wave analysis, radial artery pressure waveforms 
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ments, Houston, Tex., USA) and calibrated to the current systemic 
blood pressure. The obtained peripheral waveforms were processed 
with the SphygmoCor System (AtCor Medical, Australia) to calcu-
late an averaged aortic pulse waveform with the help of a previously 
validated generalized transfer function  [12] . Based on the calculated 
aortic pulse waveform, the augmentation pressure, a measure of ar-
terial stiffness and the central pulse pressure (central systolic blood 
pressure – central diastolic blood pressure) were determined. Final-
ly, the aortic augmentation index, defined as the ratio of augmenta-
tion pressure to the central pulse pressure (augmentation pressure/
central pulse pressure × 10), was calculated  [13] . The augmentation 
index indicates the size of the increase or decrease in pulse height as 
a result of the reflected pulse wave expressed in percent. To measure 
the carotid-femoral PWV, distance from the femoral recording site 
to the carotid recording site was determined at the body surface. Af-
terwards, ECG-triggered pulse wave recordings were performed se-
quentially at the femoral and carotid arteries using an arterial to-
nometer adjusted to systemic blood pressure, which was measured 
directly before the PWV analysis. PWV was calculated based on the 
determined propagation time from the femoral waveform to the ca-
rotid waveform and the distance between the two recording sites.
 Static and Dynamic Retinal Vessel Analysis 
 Digital fundus imaging and retinal vessel analysis were per-
formed with the Dynamic Vessel Analyzer (DVA; IMEDOS 
GmbH, Jena, Germany) as described previously  [14, 15] . In short, 
30 min after initiation of mydriasis using 1% tropicamide eye 
drops, each participant underwent 7-field fundus photography us-
ing the Visualis system (IMEDOS, FF450plus, 535–561 nm, 30° 
image, 1,840 × 1,360 pixels). The arterial and venous diameters 
were measured. Subsequently, dynamic vessel analysis was per-
formed allowing noninvasive evaluation of microvascular func-
 Table 1.  Baseline patient characteristics and clinical data
Pioglitazone Placebo p
Total number of patients 27 27
Age, years 59.5 ± 10.4 62.2 ± 10.0 n.s.
Male 21 (77.8) 23 (85.2) n.s.
BMI 27.7 ± 3.7 27.7 ± 3.2 n.s.
Current smoking 11 (40.7) 9 (33.3) n.s.
Hypertension 22 (81.5) 21 (77.8) n.s.
Dyslipidemia 21 (77.8) 21 (77.8) n.s.
Previous MI 10 (37.0) 9 (33.3) n.s.
Index event
NSTEMI 6 (22.2) 6 (22.2) n.s.
uAP 21 (77.8) 21 (77.8) n.s.
Concomitant medications
Antiplatelet agent 27 (100) 27 (100) n.s.
β-Blocker 25 (92.6) 26 (96.3) n.s.
ACE inhibitor 23 (85.2) 20 (74.1) n.s.
Angiotensin receptor blocker 6 (22.2) 7 (25.9) n.s.
Atorvastatin 20 mg 27 (100 27 (100) n.s.
 Values are means ± SD or n (%). MI = Myocardial infarction; 
NSTEMI = non-ST-elevation myocardial infarction; uAP = un-
stable angina pectoris; n.s. = not statistically significant. 




Baseline 83.1 ± 11.3 84.5 ± 11.8 n.s.
At 9 months 85.5 ± 11.9 83.2 ± 12.7 n.s.
Difference 2.4 ± 6.2      – 1.0 ± 5.7 0.04*
Systolic blood pressure, mm Hg
Baseline 136.3 ± 19.5 135.7 ± 22.0 n.s.
At 9 months 132.4 ± 19.7 130.6 ± 21.2 n.s.
Difference     – 3.8 ± 27.9      – 5.5 ± 23.8 n.s.
Diastolic blood pressure, mm Hg
Baseline 79.5 ± 11.4 77.1 ± 13.5 n.s.
At 9 months 76.6 ± 10.3 76.6 ± 10.0 n.s.
Difference     – 2.9 ± 14.0      – 0.7 ± 18.0 n.s.
Triglycerides, mmol/l
Baseline 1.6 ± 0.9 1.4 ± 0.6 n.s.
At 9 months 1.4 ± 0.7 1.5 ± 1.1 n.s.
Difference     – 0.2 ± 0.8 0.1 ± 0.8 n.s.
Total cholesterol, mmol/l
Baseline   5.0 ± 1.0 4.8 ± 1.4 n.s.
At 9 months   4.8 ± 1.1 4.3 ± 0.9 n.s.
Difference  – 0.2 ± 1.4      – 0.4 ± 1.3 n.s.
LDL cholesterol, mmol/l
Baseline   3.1 ± 1.0 3.1 ± 1.1 n.s.
At 9 months   2.8 ± 1.0 2.5 ± 0.6 n.s.
Difference  – 0.3 ± 1.1      – 0.5 ± 1.0 n.s.
HDL cholesterol, mmol/l
Baseline   1.3 ± 0.3 1.2 ± 0.3 n.s.
At 9 months   1.4 ± 0.3 1.3 ± 0.3 n.s.
Difference   0.1 ± 0.3 0.1 ± 0.4 n.s.
CETP activity, pmol/ng CETP/h (mean ± SEM)
Baseline   4.68 ± 0.67 4.48 ± 0.63 n.s.
After 3 months   5.07 ± 0.58 4.57 ± 0.59 n.s.
CETP concentration, ng/ml (mean ± SEM)
Baseline 15.58 ± 4.20 12.91 ± 2.83 n.s.
After 3 months 13.02 ± 2.98 14.74 ± 3.56 n.s.
hsCRP, mg/l (median [25–27%])
Baseline   2.7 [1.1 – 6.2] 1.8 [1.3 – 4.0] n.s.
At 9 months   1.8 [0.5 – 2.7] 1.2 [0.6 – 1.4] n.s.
Difference  – 0.5 [–1.6 to –1.0]     – 0.9 [–3.5 to 0.4] n.s.
White blood cell count, Gpt/l (median [25 – 75%])
Baseline   7.1 [5.6 – 10.4] 8.5 [5.9 – 9.6] n.s.
At 9 months   6.1 [5.0 – 7.6] 7.2 [5.3 – 8.3] n.s.
Difference  – 0.7 [–1.9 to 2.0]     – 1.3 [–2.6 to 0.1] n.s.
Glycated hemoglobin, %
Baseline   5.7 ± 0.4 5.7 ± 0.5 n.s.
At 9 months   5.7 ± 0.4 5.8 ± 0.4 n.s.
Difference  – 0.02 ± 0.34      – 0.1 ± 0.31 n.s.
Aspartate aminotransferase, μkat/l
Baseline   0.64 ± 0.47 0.66 ± 0.83 n.s.
At 9 months   0.42 ± 0.10 0.53 ± 0.45 n.s.
Difference  – 0.21 ± 0.45      – 0.13 ± 0.55 n.s.
Alanine aminotransferase, μkat/l
Baseline   0.57 ± 0.33   0.58 ± 0.81 n.s.
At 9 months   0.41 ± 0.18   0.42 ± 0.19 n.s.
Difference  – 0.16 ± 0.31  – 0.16 ± 0.75 n.s.
Creatinine, μmol/l
Baseline   85.6 ± 27.6 83.8 ± 10.3 n.s.
At 9 months   91.1 ± 25.0 86.5 ± 15.6 n.s.
Difference   5.4 ± 18.3 2.7 ± 12.6 n.s.
 Values are means ± SD unless otherwise indicated. n.s. = Not statisti-
















   
   
   
   
   


























tion by measuring the diameter of retinal arterioles and venules 
continuously. For this analysis, after a baseline recording of 30 s, 
three periods of flicker light stimulation (20-second duration) in-
terrupted by steady fundus illumination (50-second duration) was 
performed. Baseline vessel diameters were obtained by averaging 
the baseline records. The peak dilation was defined as the largest 
vessel diameter at the end of each flicker stimulation, averaged 
across three flicker periods. Changes in ocular vessel diameters 
were expressed as percent change over baseline values.
 Measurement of the Common Carotid IMT 
 IMT measurement was performed while the patient was lying 
in the supine position. IMT was determined in the common ca-
rotid artery 10 mm proximal to the bifurcation at the transducer 
far vessel wall using a Phillips iE33 TM ultrasound machine with a 
linear transducer. The maximum end-diastolic IMT measure-
ments were performed bilaterally at three different scanning angles 
with the help of digital callipers. The six tracings were then aver-
aged to calculate the mean IMT.
 Laboratory Studies 
 CETP concentration and activity were determined from the pa-
tients at two time points (study begin and after 3 months of treat-
ment). CETP activity was measured from conserved serum sam-
ples with a CETP activity fluorometric assay kit (Abcam, ab65383) 
according to the manufacturer’s protocol on a Synergy HT 
(BioTek) multimode plate reader under the usage of a fluorescent 
excitation filter 485 nm/20 nm and an emission filter 528 nm/20 
nm. CETP concentration within the serum was measured with a 
CETP ELISA kit (Abnova, KA1152) from the same serum samples. 
Concentration, activity, and normalized activity were calculated 
according to the supplier’s standards.
 Statistical Analysis 
 All variables were analyzed for normality with the graphical 
method of normal probability-quantile plot in combination with 
the Kolmogorov-Smirnov test. Results of continuous variables are 
expressed as means ± SD. Statistical analyses were done using a 
2-tailed, unpaired Student’s t test. 
 Continuous nonnormally distributed data are presented as me-
dians (interquartile ranges). Differences between nonnormally 
distributed variables were compared with the Mann-Whitney U 
test. The level of significance was set to p < 0.05. Categorical vari-
ables are presented as total numbers with comparisons using χ 2 
and Fisher’s exact tests.
 Results 
 Study Population, Safety Endpoints, and Vessel 
Baseline Characteristics 
 From March 2007 to September 2010, 54 patients were 
involved in the prospective, randomized study. Both 
treatment groups were well balanced concerning demo-
graphics and clinical baseline characteristics ( table  1 ). 
There were no relevant differences in age, gender, comor-
bidities, or concomitant medications. 
 Clinical and Biochemical Outcome after 9 Months 
 The clinical and biochemical outcome data are sum-
marized in  table 2 . The body weight in pioglitazone pa-
tients increased significantly by 2.4 kg, whereas the con-
trol patients revealed a weight loss of 1 kg. The systolic 
and diastolic blood pressures decreased equally in both 
treatment groups. The biochemical markers creatinine, 
aspartate aminotransferase, and alanine aminotransfer-
ase showed no relevant changes after 9 months in both 
treatment groups. As markers of systemic inflammation, 
white blood cell count and hsCRP were determined. Both 
inflammation markers declined slightly in both treat-
ment groups after 9 months. However, no significant dif-
ferences of these inflammation markers could be detected 
between the pioglitazone group and the placebo group. 
Further, no relevant changes in levels of triglycerides, to-
tal cholesterol, LDL cholesterol, and high-density lipo-
protein (HDL) cholesterol as common values of lipid me-
tabolism could be observed in either treatment group. 
Additionally, CETP concentration and activity were de-
termined. It is supposed that a reduction in CETP activ-
ity inhibits the atherosclerotic plaque development by in-
creasing the plasma level of HDL cholesterol. However, 
after treatment with pioglitazone, no relevant changes in 
CETP concentration and activity could be measured 
compared to controls. Finally, the glycated hemoglobin 
level was not affected after treatment with pioglitazone.
 No significant differences in the safety endpoints be-
tween the two treatment groups were observed. Thus, the 
incidences of adverse events were similar among the 
groups after 9 months: peripheral edema = 1 in the pio-
glitazone group and 1 in the placebo group; recent onset 
of dyspnea = 2 in the pioglitazone group and 1 in the pla-
cebo group; recent onset of fatigue = 1 in the pioglitazone 
group and 1 in the placebo group, and stable angina pec-
toris = 4 in the pioglitazone group and 5 in the placebo 
group.
 Clinical Function of Noncoronary Vessels at Baseline 
and after 9 Months 
 To investigate the influence of the therapy with pio-
glitazone on the arterial stiffness in ‘large’ vessels, analysis 
of artery pulse wave and carotid-femoral PWV were per-
formed at baseline and after 9 months. In these examina-
tions, no relevant changes in PWV and augmentation in-
dex were found in either the pioglitazone group or the 
placebo group ( table 3 ). As an additional parameter for 
the development of atherosclerosis in the ‘large’ vessels, 
the common carotid IMT was determined. After 9 
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mined in either of the treatment groups. The mean IMT 
was 0.8 mm in both groups at baseline and after 9 months 
( table 3 ). To examine the changes in microcirculation un-
der treatment with pioglitazone, static and dynamic reti-
nal vessel analysis were performed ( table 3 ). In static ret-
inal vessel analysis, no significant differences were ob-
served in either the arterial diameters (pioglitazone 112.1 
± 23.3 μm vs. placebo 117.9 ± 21.5 μm) or in the venous 
diameter (pioglitazone 166.8 ± 23.8 μm vs. placebo 161.9 
± 20.6 μm) after 9 months. In the dynamic analysis, the 
arterial diameter change was equal in the placebo and in 
the pioglitazone groups as well.
 Discussion 
 The systemic medical treatment of atherosclerosis re-
mains unsatisfactory despite advanced therapy with anti-
thrombotics, statins, and antihypertensive therapy. 
Therefore, further pharmacological inhibition of this sys-
temic disease is desirable. In this context, the current 
study observed for the first time the potential antiathero-
sclerotic effects of the insulin-sensitizing thiazolidinedi-
one pioglitazone in nondiabetic patients.
 The salient finding of the clinical part of the PPP Trial 
was that the additional treatment with pioglitazone was 
not able to influence the function of peripheral vessels as 
important clinical surrogate parameters for the cardio-
vascular outcome. In the current trial, no relevant chang-
es in the IMT could be determined after pioglitazone 
treatment. In contrast, the Chicago trial showed that 
compared with glimepiride, pioglitazone slowed down 
the progression of carotid IMT in type 2 diabetic patients 
over a treatment period of 18 months even though the 
absolute values were very low (difference between both 
groups: –0.013 mm)  [16] . This could be explained either 
by the follow-up period being too short or by the normal 
glycemic metabolism in the current trial. Next, the aortic 
stiffness was observed with the help of PWV and the aug-
mentation index, which are strong independent predic-
tors of all-cause and cardiovascular mortality  [2] . Also, 
these surrogate parameters did not differ significantly af-
ter treatment with pioglitazone. Finally, microvascular 
function was examined with the help of static and dy-
namic vessel analysis. In these analyses, pioglitazone 
treatment did improve endothelial function in retinal 
vessels.
 Different studies have shown that the antiatheroscle-
rotic effect of pioglitazone cannot solely be explained by 
its positive effect on glycemia  [16–18] . For that reason, we 
hypothesized that atherosclerotic plaque regression is 
partially attributable to lipid-modulating effects, anti-in-
flammatory effects or a combination of these effects. 
However, the current data showed no relevant changes in 
the levels of triglycerides, total cholesterol, LDL choles-
terol, HDL cholesterol, and the inflammatory markers 
such as white blood cell count and hsCRP after 9 months 
of pioglitazone treatment.
 These results are contradictory to previous studies, 
which postulated a positive influence on lipid metabolism 
in type 2 diabetes patients. Thus, a previous study inves-
tigated the effect of pioglitazone and another thiazolidine-
dione rosiglitazone on dyslipidemia in 802 diabetic pa-
tients. In this trial, the administration of pioglitazone 
compared with rosiglitazone was associated with signifi-
cant improvements in triglycerides, HDL cholesterol, and 
LDL particle concentration independent of glycemic con-
trol  [17] . These positive effects of pioglitazone on diabet-
 Table 3.  Noncoronary vessel function 9 months after treatment 
with pioglitazone
Pioglitazone  Placebo p
Common carotid IMT, mm
Baseline 0.87 ± 0.34  0.80 ± 0.14 n.s.
At 9 months 0.85 ± 0.30  0.79 ± 0.15 n.s.
Difference 0.01 ± 0.17 – 0.01 ± 0.13 n.s.
Artery pulse wave analysis and carotid-femoral PWV
Aortic augmentation index, %
Baseline 26.3 ± 10.2  19.9 ± 11.8 n.s.
At 9 months 23.1 ± 10.4  24.9 ± 9.8 n.s.
Difference      – 0.7 ± 2.3  5.6 ± 12.1 n.s.
PWV, m/s
Baseline 12.9 ± 3.5  13.9 ± 3.6 n.s.
At 9 months 14.3 ± 4.4  14.2 ± 4.2 n.s.
Difference 0.46 ± 2.10  0.72 ± 2.10 n.s.
Static and dynamic retinal vessel analysis
Retinal arterial diameter, μm
Baseline 116.7 ± 16.3  114.9 ± 18.2 n.s.
At 9 months 112.1 ± 23.3  117.9 ± 21.5 n.s.
Difference      – 4.7 ± 31.9  3.0 ± 14.7 n.s.
Retinal venous diameter, μm
Baseline 162.8 ± 31.0  147.1 ± 19.0 n.s.
At 9 months 166.8 ± 23.8  161.9 ± 20.6 n.s.
Difference 4.0 ± 15.2  14.8 ± 25.0 n.s.
Arterial diameter change, %
Baseline 1.78 ± 3.32  2.54 ± 4.69 n.s.
At 9 months 1.89 ± 0.49  0.81 ± 2.40 n.s.
Difference 0.11 ± 3.42 – 1.73 ± 6.28 n.s.
















   
   
   
   
   


























ic dyslipidemia were confirmed in the Chicago trial  [16] . 
On the other hand, a previous study with nondiabetic pa-
tients could not find any changes in lipid parameters after 
treatment with pioglitazone, similar to the current non-
diabetic study population  [19] . Additionally, in the pres-
ent trial, no relevant change in CETP concentration and 
activity could be measured after treatment with pioglit-
azone compared to controls. It is thought that a reduction 
of CETP activity increases the plasma level of HDL cho-
lesterol  [20, 21] . Next, the anti-inflammatory component 
of pioglitazone, which has often been described, could ex-
plain its antiatherosclerotic effect  [10, 22, 23] . Also in the 
current trial the white blood cell count and hsCRP were 
found to be decreased after pioglitazone treatment. How-
ever, a significant difference between the two treatment 
groups could not be detected because of the large varia-
tion of these inflammatory markers. Possibly, a measure-
ment of further cytokine levels like IL-1, IL-6, or TNF-α 
could better prove the anti-inflammatory effect of pio-
glitazone. On the other hand, the acute coronary syn-
drome itself, as it was required in the inclusion criteria of 
the current trial, could influence all inflammatory mark-
ers more than the underlying chronic coronary artery dis-
ease. In summary, based on the current study, the anti-
atherosclerotic effect of pioglitazone in peripheral vessels 
in nondiabetic patients remains speculative. 
 It is noteworthy that the current study has some limi-
tations. The current trial was not primarily designed to 
investigate the clinical outcome after treatment with pio-
glitazone in nondiabetics. Further, the follow-up period 
of the current trial was too short to investigate the clinical 
outcome. Thus, the benefit of pioglitazone on the cardio-
vascular morbidity and mortality in nondiabetic patients 
remains uncertain despite the unchanged surrogate pa-
rameter.  Further, only patients with a clinically relevant 
coronary artery disease were included. It is unclear wheth-
er our results are consistent in primary prevention of ath-
erosclerosis. Another limitation of the study was the rela-
tively small number of patients, so the work should be 
understood as a pilot study. An additional limitation of 
the study was that the concomitant medication with ator-
vastatin and antiplatelet agents may influence the vessel 
function on top of pioglitazone, which could lead to a 
masking effect of pioglitazone action. Despite these limi-
tations, to the best of our knowledge, the current study 
did not show any relevant changes in the vessel wall func-
tion after treatment with pioglitazone in nondiabetics. 
 Whether pioglitazone influences the clinical cardio-
vascular outcome in nondiabetic patients remains specu-
lative, especially in light of recent studies regarding the 
cardiovascular safety of pioglitazone. Therefore, the anti-
atherosclerotic effect of pioglitazone on the cardiovascu-
lar outcome in nondiabetics should be investigated in 
larger outcome trials with longer follow-up periods.
 Our findings have clinical implications for the devel-
opment of a novel systemic antiatherosclerotic therapy.
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